The DOI matches its Crossref record.
Combination Foscarnet and Ganciclovir Therapy vs Monotherapy for the Treatment of Relapsed Cytomegalovirus Retinitis in Patients With AIDS: The Cytomegalovirus Retreatment Trial
Abstract
OBJECTIVES: To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis. DESIGN: Multicenter, randomized, controlled clinical trial. SETTING: Ophthalmology, and acquired immunodeficiency syndrome (AIDS) services at tertiary care medical centers. PATIENTS: Two hundred seventy-nine patients with AIDS and either persistently active or relapsed CMV retinitis. INTERVENTION: Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group). OUTCOMES: Mortality, retinitis progression, visual acuity, visual fields, and morbidity. RESULTS: The mortality rate was similar among the three groups. Median survival times were as follows: foscarnet group, 8.4 months; ganciclovir group, 9.0 months; and combination therapy group, 8.6 months (P=.89). Comparison of retinitis progression, as evaluated in a masked fashion by the centralized Fundus Photograph Reading Center (FPRC), revealed that combination therapy was the most effective regimen for controlling the retinitis. The median times to retinitis progression were as follows: foscarnet group, 1.3 months; ganciclovir group, 2.0 months; and combination therapy group, 4.3 months (P<.001). Although no difference could be detected in visual acuity outcomes, visual field loss and retinal area involvement on fundus photographs both paralleled the progression results, with the most favorable results in the combination therapy group. The rates of visual field loss were as follows: foscarnet group, 28 degrees per month; ganciclovir group, 18 degrees per month; combination therapy group, 16 degrees per month (P=.009); and the rates of increase of retinal area involved by CMV were as follows: foscarnet group, 2.47% per month; ganciclovir group, 1.40% per month; and combination therapy group, 1.19% per month (P=.04). While side effects were similar among the three treatment groups, combination therapy was associated with the greatest negative impact of treatment on quality-of-life measures. CONCLUSION: For patients with AIDS and CMV retinitis whose retinitis has relapsed and who can tolerate both drugs, combination therapy appears to be the most effective therapy for controlling CMV retinitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kotton, C. N., Kumar, D., Caliendo, A. M., Åsberg, A., Chou, S., Snydman, D. R., Allen, U., & Humar, A. (2010) · Transplantation · doi:10.1097/tp.0b013e3181cee42f · Cited by 965
Antiviral Drug Resistance of Human Cytomegalovirus
Lurain, N. S., & Chou, S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00009-10 · Cited by 596
Masur, P. B. H., Kaplan, J. E., & Holmes, K. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00002 · Cited by 567
Wu, A. W., Revicki, D. A., Jacobson, D., & Malitz, F. E. (1997) · Quality of Life Research · doi:10.1023/a:1018451930750 · Cited by 546
Crumpacker, C. S. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609053351007 · Cited by 382
Metadata
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 1996-01-01
- Volume
- 114
- Issue
- 1
- Pages
- 23
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W4210752375
- Cited by
- 178
- References
- 0
- FWCI
- 18.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Foscarnet and Ganciclovir Therapy vs Monotherapy for the Treatment of Relapsed Cytomegalovirus Retinitis in Patients With AIDS: The Cytomegalovirus Retreatment Trial. https://app.cochat.ai/papers/10.1001/archopht.1996.01100130021004
- The paper
- Combination Foscarnet and Ganciclovir Therapy vs Monotherapy for the Treatment of Relapsed Cytomegalovirus Retinitis in Patients With AIDS: The Cytomegalovirus Retreatment Trial. (1996). Archives of Ophthalmology. https://doi.org/10.1001/archopht.1996.01100130021004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.